The Center for Biosimilars® recaps the top news for the week of December 3, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 3.
Number 5: A new study found that CT-P10, a rituximab biosimilar, demonstrated comparable progression-free survival, sustained response, and overall survival with the reference product in patients with previously untreated advanced follicular lymphoma.
Number 4: The American College of Rheumatology and the National Psoriasis Foundation released a new treatment guideline for psoriatic arthritis that contains evidence-based recommendations on caring for patients with this inflammatory disease.
Number 3: A recent study found that using only tbo-filgrastim in treating neutropenia for patients undergoing cytotoxic chemotherapy in the Veterans Health Administration led to cost savings.
Number 2: A study presented at the American Society of Hematology’s annual meeting found that subcutaneously administered rituximab has the potential to save both cost and time.
Number 1: Celltrion has announced that the European Medicines Agency has accepted for review an extension marketing authorization application for a subcutaneous formulation of the company’s biosimilar infliximab, CT-P13.
Finally, last week, our e-newsletter asked if the FDA’s efforts to increase competition are enough to curb rising drug prices.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.